Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Mechanism of action of CI-958, a potential agent for prostate cancer in phase II trials

Nov. 24, 1998

Genta initiates another phase I/IIa prostate cancer trial with G-3139

Nov. 24, 1998

Gastrimmune enters phase III trials for pancreatic cancer

Nov. 20, 1998

Parke-Davis identifies potent inhibitor of PDGF receptor TK and PDGF-dependent tumor growth

Nov. 20, 1998

Antitumor tetramic acid compound produced by Streptomyces

Nov. 20, 1998

Clarion prepares novel compounds for cancer, psoriasis and inflammation

Nov. 20, 1998

Vertex reports preliminary data on Incel in soft tissue carcinoma and initiates new phase II trial

Nov. 20, 1998

MPIF advances to phase II trials in cancer patients

Nov. 19, 1998

First potent, orally active LHRH antagonist discovered by Takeda

Nov. 19, 1998

U.S. patent protects methods of angiogenesis inhibition using Xoma's BPI products

Nov. 19, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...